tofacitinib / Generic mfg. - LARVOL DELTA

Design, synthesis and biological evaluation of coumarin-based HDAC6 inhibitors for the treatment of ulcerative colitis. (PubMed, Bioorg Med Chem Lett) - "Notably, its therapeutic efficacy was comparable to that of tofacitinib. These findings suggested that compound 24 was a promising anti-inflammatory candidate for selective HDAC6 inhibitor and deserves further investigation."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • HDAC1

Dissolving microneedle co-deliver mitochondria-targeted Nanozyme and Tofacitinib for synergistic treatment of Rosacea. (PubMed, J Control Release) - "Furthermore, in vivo studies on an LL-37-induced rosacea model demonstrated that Tof/WTCeNPs-MN significantly ameliorated disease symptoms. Collectively, these findings establish the Tof/WTCeNPs-MN system as a promising, multifunctional therapeutic platform for rosacea."

Journal • Dermatology • Inflammation • Rosacea

Early detection of emerging safety signals in GVHD prophylaxis agents using a 12-year faers "slope-watch" approach (ASH 2025) - "In addition to tacrolimus and cyclosporine, contemporary prophylaxis regimens employ sirolimus and everolimus, mycophenolate mofetil, methotrexate, post-transplant cyclophosphamide (PTCy), JAK inhibitors (ruxolitinib, baricitinib, tofacitinib), co-stimulation blockade with abatacept, gut-homing integrin antagonism via vedolizumab, and the ROCK2 inhibitor belumosudil. Sequential IC-Δ offers a robust, forward-looking pharmacovigilance framework that identifies adverse event acceleration 12–24 months before regulatory action. By emphasizing directional change and incorporating a simple confidence approximation, this approach enhances early signal detection in large safety datasets. Integration with electronic health records, regulatory pipelines, and interactive dashboards could further streamline horizon scanning and improve patient safety in GVHD prophylaxis."

Clinical • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Dyslipidemia • Graft versus Host Disease • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Metabolic Disorders • Pneumonia • Rare Diseases • Respiratory Diseases • Septic Shock

Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes (ASH 2025) - "PRO indicated substantial impairment, with 48% reporting moderate to severelimitations on EQ-5D and a median EQ-VAS score of 60.Steroid-sparing therapies included azacytidine (AZA), JAK inhibitors, conventional immunomodulatorsand cytokine blockers (TNFα, IL-1, IL-6)...JAK inhibitors (ruxolitinib, upadacitinib,tofacitinib, baricitinib) were given in 27%; 53% were switched due to lack of efficacy after a medianduration of 4 mo...Immunomodulatorsand/or cytokine blockers were used in 36% (median 2 agents, range 1–4); 40% had at least a minor clinicalresponse, most commonly with methotrexate or anti-IL-1 agents, although all anti-IL-1 treatments wereeventually discontinued due to intolerance...Our data confirm theconsiderable heterogeneity of both disease manifestations and therapeutic responses, highlighting theneed to strengthen interdisciplinary collaboration and improve treatment standards. Even though aproportion of patients had a disease onset even before VEXAS was..."

Clinical • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Monoclonal Gammopathy • Musculoskeletal Pain • Myelodysplastic Syndrome • Ocular Inflammation • Rheumatology • ASXL1 • DNMT3A • IL6 • SRSF2 • TET2 • TNFA

Single-cell chromatin profiling reveals early epigenetic reprogramming, subtype-specific regulatory networks, and JAK/STAT–IRF vulnerabilities in high-risk chronic myeloid leukemia (ASH 2025) - "To identify these resistant states, we performed single-cell (SC) multi-omic profiling (scRNA-seq, scATAC-seq, and targeted mutational analysis) on pre-treatment bone marrow (BM) mononuclear cells from(n=24, CML) three clinical groups (optimal imatinib [IM] responders, suboptimal IM responders, IM failurewith BC progression; n=5/5/6), normal BM (n=4), and BC samples (myeloid n=2, lymphoid n=2)...Although tofacitinib alone showed minimalcytotoxicity, it markedly sensitized BC cells (n=4) to TKIs (~90% killing) while sparing normal progenitors(~25% killing). Thus, mapping the CML epigenetic landscape identified core transformation regulatorsand revealed actionable therapeutic opportunities.This study presents the first scATAC atlas of CML resistance and progression, revealing that: (1) Epigeneticreprogramming in CP precedes BC transformation; (2) Distinct TF networks drive BC subtypes; and (3) JAKinhibition is a novel strategy to dismantle JAK/STAT-IRF activation in..."

Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Myeloproliferative Neoplasm • ABL1 • CEBPA • IL2 • JAK1 • JAK2 • STAT1 • STAT5 • TNFA

BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata. (PubMed, Br J Dermatol) - "However, tofacitinib demonstrated much greater efficacy. Larger studies are warranted to confirm these findings and explore the underlying mechanisms behind the differences, particularly in alkaline phosphatase activity."

Clinical • Journal • Alopecia • CNS Disorders • Dermatology • Dyslipidemia • Hematological Disorders • Immunology • Infectious Disease • Leukopenia • Nephrology • Pain • Renal Calculi • Varicella Zoster

P068 Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: a randomized controlled trial. (PubMed, Br J Dermatol) - "In conclusion, tofacitinib is more effective than OMP in the treatment of active nonsegmental vitiligo, with greater extent of repigmentation and lower rates of treatment failure. However, both treatment modalities have statistically similar efficacy in terms of disease stabilization and relapse."

Clinical • Journal • Dermatology • Immunology • Vitiligo

BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases. (PubMed, Br J Dermatol) - "For eczema, therapies such as dupilumab show limited evidence in also treating AA...For instance, baricitinib is licensed for both AD and AA, while upadacitinib is licensed for AD and is currently in phase III trials for AA. Amlitelimab, which targets the OX40 ligand pathway, is currently in phase III clinical trials for atopic dermatitis and in phase II trials for severe AA...In psoriasis, overlapping therapies include ustekinumab, approved for psoriasis and being studied for AA. As for patients with RA, tofacitinib is approved for moderate-to-severe disease and is also utilized in AA. Abatacept is a cytotoxic T lymphocyte-associated protein 4 (CTLA4) immunoglobin costimulatory modulator that attenuates the activation of T cells and is widely used in RA...The Global Registry of Alopecia areata disease Severity and treatment Safety (GRASS) UK is a prospective, multicentre, observational clinical registry designed to create harmonized datasets. These datasets aim to..."

Journal • Review • Alopecia • Atopic Dermatitis • CNS Disorders • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Multiple Sclerosis • Psoriasis • Rheumatoid Arthritis • Rheumatology • Vitiligo • CTLA4

BH09 Rapid resolution of chronic spontaneous urticaria with ritlecitinib in a patient with alopecia universalis. (PubMed, Br J Dermatol) - "Initial management included high-dose fexofenadine, famotidine, montelukast and omalizumab...Pulsed dexamethasone provided modest improvement in her urticaria symptoms but did not alter the progression of her alopecia...While JAK inhibitors are not established as a standard treatment for CSU, limited case series have documented the use of tofacitinib in refractory cases...The rapid and sustained symptom resolution observed in this patient suggests the potential of ritlecitinib as a novel therapeutic option for refractory CSU. Further investigation is warranted to evaluate its broader clinical applicability and efficacy in CSU management."

Journal • Alopecia • Asthma • Chronic Spontaneous Urticaria • Dermatology • Endocrine Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • Urticaria

P089 Efficacy of tofacitinib in cases of moderate-to-severe (stage 2 and stage 3) hidradenitis suppurativa: a pilot study. (PubMed, Br J Dermatol) - "Treatment options are limited, and existing therapies like adalimumab and secukinumab show inconsistent results. In conclusion, tofacitinib showed significant potential in treating moderate-to-severe HS, improving disease severity, quality of life and associated inflammation. These promising findings highlight the need for more extensive trials with controls to confirm its safety and efficacy."

Journal • Dermatology • Fibrosis • Hidradenitis Suppurativa • Immunology • Inflammation • Pain • IL6

BH01 (P078) Oral tofacitinib in management of nail lichen planus: a retrospective study. (PubMed, Br J Dermatol) - "These results suggest that oral tofacitinib is an effective and well-tolerated treatment modality in NLP. Meaningful improvements in nail disease activity and appearance were observed as early as 1 month and sustained through 3 months."

Journal • Retrospective data • Dermatology • Dermatopathology • Inflammation • Lichen Planus

P078 Oral tofacitinib in management of nail lichen planus: a retrospective study. (PubMed, Br J Dermatol) - "These results suggest that oral tofacitinib is an effective and well-tolerated treatment modality in NLP. Meaningful improvements in nail disease activity and appearance were observed as early as 1 month and sustained through 3 months."

Journal • Retrospective data • Dermatology • Dermatopathology • Inflammation • Lichen Planus

BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report. (PubMed, Br J Dermatol) - "The efficacy of ritlecitinib, an oral Janus kinase 3/TEC family inhibitor, has been demonstrated in the Allegro clinical trials...The US Food and Drug Administration issued black box warnings, citing increased risks of major adverse cardiovascular events, malignancies, venous thromboembolism (VTE) and mortality based on data from tofacitinib, baricitinib and upadacitinib in rheumatoid arthritis...The patient received intravenous broad-spectrum antibiotics for sepsis of unknown origin, hydrocortisone and vasopressor support for hypotension. She was anticoagulated with dalteparin and transitioned to apixaban as per respiratory advice for unprovoked pulmonary emboli...This case highlights a probable severe adverse event associated with ritlecitinib therapy, including pulmonary emboli and infection of unidentified source, associated with new-onset atrial fibrillation and acute kidney injury in a patient without known risk factors for VTE. Ongoing pharmacovigilance is..."

Journal • Acute Kidney Injury • Alopecia • Atrial Fibrillation • Cardiovascular • Dermatology • Endocrine Disorders • Hematological Disorders • Herpes Zoster • Hypotension • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Musculoskeletal Pain • Nephrology • Novel Coronavirus Disease • Oncology • Pain • Pneumococcal Infections • Pruritus • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Septic Shock • Varicella Zoster • Venous Thromboembolism • CRP • JAK3

BH14 Irish dermatologists' experience with Janus kinase inhibitors in alopecia areata. (PubMed, Br J Dermatol) - "Interestingly, the first JAKi option in AA was reported as baricitinib (81%)...For the second JAKi option (if the first fails), 47% of respondents chose tofacitinib, followed by upadacitinib (24%)...AA poses challenges to clinicians. While JAKis show impressive efficacy, in the absence of clear literature and global guidelines to assist clinicians managing AA with JAKis, practice varies considerably."

Journal • Alopecia • Dermatology • Immunology • Inflammation

Machine learning-based prediction of response to Janus kinase inhibitors in patients with rheumatoid arthritis using clinical data. (PubMed, Front Immunol) - "Our machine-learning models (trained and validated separately for each drug) achieved high predictive performance (tofacitinib: ROC-AUC 0.82, accuracy 80%; baricitinib: ROC-AUC 0·88, accuracy 88%), identifying key clinical factors such as total cholesterol, CRP, and specific joint swelling or tenderness for tofacitinib, and patient global assessment, joint swelling, and co-administration of hydroxychloroquine for baricitinib. Model-guided treatment selection could have improved outcomes for an additional 15% of patients by aligning each individual's predicted response with the more suitable Janus kinase inhibitor. The findings suggest that ML models can accurately predict treatment response to Janus kinase inhibitors in rheumatoid arthritis and may support personalized therapy selection to improve clinical outcomes."

Clinical data • Journal • Retrospective data • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata. (PubMed, Br J Dermatol) - "However, tofacitinib demonstrated much greater efficacy. Larger studies are warranted to confirm these findings and explore the underlying mechanisms behind the differences, particularly in alkaline phosphatase activity."

Clinical • Journal • Alopecia • CNS Disorders • Dermatology • Dyslipidemia • Hematological Disorders • Immunology • Infectious Disease • Leukopenia • Nephrology • Pain • Renal Calculi • Varicella Zoster

P114 Efficacy and safety of oral Janus kinase, tyrosine kinase 2 and phosphodiesterase 4 inhibitors in the treatment of chronic plaque psoriasis: a network meta-analysis. (PubMed, Br J Dermatol) - "After 16-24 weeks of treatment, tofacitinib and deucravacitinib had the highest efficacy, followed by apremilast, orismilast, upadacitinib and brepocitinib. Zasocitinib, a new highly selective allosteric TYK2 inhibitor, has recently demonstrated promising efficacy in the treatment of psoriasis, with 33% of patients achieving PASI 100 (complete clearance of psoriasis lesions) after just 12 weeks of treatment. In conclusion, oral TYK2 inhibitors have shown efficacy in the treatment of chronic plaque psoriasis comparable with adalimumab, with newer agents demonstrating enhanced effectiveness and surpassing PDE-4 inhibitors in therapeutic outcomes. JAK inhibitors, particularly tofacitinib, exhibit comparable efficacy to some TYK2 and PDE-4 inhibitors."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • TYK2

DP04 A case of elastosis perforans serpiginosa in a patient with trisomy 21. (PubMed, Br J Dermatol) - "Regular medications were notable for tofacitinib to treat her psoriatic arthritis, moderately potent topical steroid preparations, and coal tar shampoo to treat her scalp psoriasis...Noted associations with EPS include connective tissue diseases such as cutis laxa, pseudoxanthoma elasticum, Ehlers-Danlos syndrome (EDS), Marfan syndrome and systemic sclerosis; trisomy 21; Rothmund-Thompson syndrome; and medications such as D-penicillamine...Reported treatments include topical corticosteroids, topical retinoids, cryotherapy, topical imiquimod, narrowband ultraviolet B radiation, oral isotretinoin and ablative carbon dioxide laser, with variable results. This case highlights that EPS should be considered in patients with trisomy 21 given the association. It also highlights that when undertaking a biopsy in suspected EPS it is important to take samples from the keratotic papules to ensure diagnostic accuracy."

Journal • Dermatology • Dermatopathology • Genetic Disorders • Hurler Syndrome • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rare Diseases • Rheumatology • Scleroderma • Seronegative Spondyloarthropathies • Systemic Sclerosis

PA06 Efficacy and safety of oral tofacitinib in children with moderate-to-severe atopic dermatitis: a retrospective analysis. (PubMed, Br J Dermatol) - "Nine children (60%) were previously treated with oral steroids and three with ciclosporin. A mild transient decrease in total leucocyte count was encountered in a child. In conclusion, oral tofacitinib is considerably safe and efficacious in treating moderate-to--severe AD in children and can be useful in refractory cases."

Journal • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • JAK1

PA13 Comparison of oral minipulse dexamethasone and tofacitinib in progressive nonsegmental childhood vitiligo. (PubMed, Br J Dermatol) - "OMP showed a slightly greater trend towards earlier arrest of disease progression, while both therapies demonstrated similar repigmentation outcomes at 36 weeks. Safety profiles were acceptable, with minimal adverse events in both groups."

Clinical • Journal • Dermatology • Dyslipidemia • Gastrointestinal Disorder • Immunology • Vitiligo

Emerging role of Janus kinase inhibitors in ulcerative colitis management. (PubMed, World J Gastrointest Pharmacol Ther) - "Tofacitinib is the first approved JAK inhibitor for the treatment of moderate-to-severe UC...These adverse effects have stressed the development of more selective agents such as upadacitinib and filgotinib...This review also highlights future directions, including the potential of selective JAK1 inhibition and the role of personalized medicine in refining therapeutic decisions. Understanding the emerging place of JAK inhibitors within the UC treatment strategies offers excellent opportunities to increase patient care and long-term disease management."

Journal • Review • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • JAK1

Understanding Cardiovascular Events With JAK Inhibitors: Similarities and Differences of the Vascular Effects Between Different JAK Inhibitors on Endothelial Cells Exposed to Inflammatory Cytokines. (PubMed, ACR Open Rheumatol) - "All JAKi reduced EC inflammation but most JAKi could not prevent the up-regulation of adhesion molecules or the increase in procoagulant and the decrease in anticoagulant factors triggered by proinflammatory cytokines. Peficitinib and fedratinib exhibited cytotoxic effects causing EC apoptosis."

Journal • Cardiovascular • Oncology • ANXA5 • CXCL8 • ICAM1 • IL17A • IL6 • TNFA • VCAM1

Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in VigiBase. (PubMed, Clin Transl Sci) - "This study analyzed VigiBase, the World Health Organization global pharmacovigilance database of individual case safety reports (ICSRs), to assess signals of disproportionate reporting (SDRs) for pregnancy-related adverse drug reactions (ADRs) reported with systemic JAKIs, including abrocitinib, baricitinib, deucravacitinib, fedratinib, filgotinib, itacitinib, momelotinib, pacritinib, peficitinib, ritlecitinib, ruxolitinib, tofacitinib, and upadacitinib. Findings should be interpreted cautiously given the limitations of spontaneous reporting systems and the exploratory nature of the analysis. Further studies are needed to better characterize the JAKI safety in pregnancy."

Adverse drug reaction • Adverse events • Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Sustaining Treatment Response in Alopecia Areata Through Tofacitinib Dose Tapering: A Single-Center Retrospective Study. (PubMed, J Am Acad Dermatol) - "A patient-centered tofacitinib tapering strategy is feasible for responders and may reduce treatment burden without compromising efficacy."

Journal • Retrospective data • Alopecia • Immunology

Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review. (PubMed, Int J Dermatol) - No abstract available

Journal • Alopecia • Immunology